Tech Company Financing Transactions
Be Biopharma Funding Round
Be Biopharma, based in Cambridge, secured $130 million from Arch Venture Partners, Alta Partners and Atlas Venture.
Transaction Overview
Company Name
Announced On
4/14/2022
Transaction Type
Venture Equity
Amount
$130,000,000
Round
Series B
Investors
Proceeds Purpose
Be Biopharma will channel the funds into advancing pipeline candidates initially targeting oncology and rare diseases, though the company has yet to publicly disclose clinical timelines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. B200 # 001
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Be Bio is a leader in developing engineered B cells as a new category of cellular medicines. B cells are one of the most unique and versatile populations of cells in the body, playing a key role in humoral immunity and in modulating immune cell behavior in tumors and chronically inflamed tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Steinberg
Co-Founder
Lea Hachigian
President
Aleks Radovic-Moreno
Browse more venture capital transactions:
Prev: 4/14/2022: People Mesh venture capital transaction
Next: 4/14/2022: Offor Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs